NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Roche Holding AG (OTCQX: RHHBY)

 
RHHBY Technical Analysis
5
As on 9th Jun 2023 RHHBY STOCK Price closed @ 39.15 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 44.63 & Strong Sell for SHORT-TERM with Stoploss of 49.34 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

RHHBYSTOCK Price

Open 39.27 Change Price %
High 39.29 1 Day -0.25 -0.63
Low 38.97 1 Week -1.11 -2.76
Close 39.15 1 Month -0.50 -1.26
Volume 5111700 1 Year -11.53 -22.75
52 Week High 53.44 | 52 Week Low 34.88
 
OTCQX USA Most Active Stocks
OREAF 0.02 -71.43%
RHHBY 39.15 -0.63%
GBTC 13.54 -2.24%
ETHE 7.80 -2.99%
EMHTF 0.04 33.33%
VYGVF 0.15 -6.25%
ZNOG 0.08 14.29%
DANOY 11.58 -2.11%
LGDTF 0.31 -3.12%
CURLF 2.96 -1.33%
 
OTCQX USA Top Gainers Stocks
VVCIF 0.02 100.00%
JRSS 0.07 40.00%
EMHTF 0.04 33.33%
POPRF 0.50 28.57%
POPRF 0.50 28.57%
UGDIF 0.05 25.00%
IDXG 1.20 18.81%
YGTFF 0.07 16.67%
ZNOG 0.08 14.29%
AUMBF 0.08 14.29%
 
OTCQX USA Top Losers Stocks
AKOWF 0.05 -76.19%
OREAF 0.02 -71.43%
ETRGF 0.01 -50.00%
APLIF 0.02 -33.33%
LOWLF 0.03 -25.00%
ZNOGW 1.05 -19.23%
ENZN 0.12 -14.29%
AUXXF 0.12 -14.29%
MACE 0.06 -14.29%
IDAID 4.11 -11.61%
 
 
RHHBY
Daily Charts
RHHBY
Intraday Charts
Whats New @
Bazaartrend
RHHBY
Free Analysis
 
RHHBY Important Levels Intraday
RESISTANCE39.77
RESISTANCE39.57
RESISTANCE39.45
RESISTANCE39.32
SUPPORT38.98
SUPPORT38.85
SUPPORT38.73
SUPPORT38.53
 
RHHBY Forecast February 2024
4th UP Forecast50.96
3rd UP Forecast47.17
2nd UP Forecast44.83
1st UP Forecast42.49
1st DOWN Forecast35.81
2nd DOWN Forecast33.47
3rd DOWN Forecast31.13
4th DOWN Forecast27.34
 
RHHBY Weekly Forecast
4th UP Forecast43.60
3rd UP Forecast42.17
2nd UP Forecast41.29
1st UP Forecast40.41
1st DOWN Forecast37.89
2nd DOWN Forecast37.01
3rd DOWN Forecast36.13
4th DOWN Forecast34.70
 
RHHBY Forecast2024
4th UP Forecast76.07
3rd UP Forecast64.23
2nd UP Forecast56.91
1st UP Forecast49.59
1st DOWN Forecast28.71
2nd DOWN Forecast21.39
3rd DOWN Forecast14.07
4th DOWN Forecast2.23
 
 
RHHBY Other Details
Segment EQ
Market Capital 340336410624.00
Sector Healthcare
Industry Drug Manufacturers-General
Offical website >
 
RHHBY Address
RHHBY
 
RHHBY Latest News
 
Your Comments and Response on Roche Holding AG
 
RHHBY Business Profile
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. The company has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors, as well as with Surface Oncology, Inc. to evaluate SRF388. It also has a clinical collaboration with Carrick Therapeutics, Ltd. to evaluate a novel combination of Carrick's samuraciclib and its giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland. Address: Konzern Hauptsitz, Basel, Switzerland, 4070
 
2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service